Alpine Immune Sciences (NASDAQ:ALPN) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative net margin of 214.70% and a negative return on equity of 59.07%.

Alpine Immune Sciences stock traded up $0.84 during mid-day trading on Friday, hitting $7.55. The company had a trading volume of 92,046 shares, compared to its average volume of 96,234. The company has a current ratio of 2.75, a quick ratio of 2.75 and a debt-to-equity ratio of 0.03. The stock’s 50 day moving average price is $8.56 and its two-hundred day moving average price is $10.01. Alpine Immune Sciences has a 12 month low of $6.00 and a 12 month high of $15.14.

A number of institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its holdings in Alpine Immune Sciences by 7.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 32,417 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 2,294 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Alpine Immune Sciences by 1.4% in the first quarter. Vanguard Group Inc. now owns 707,598 shares of the biotechnology company’s stock worth $6,347,000 after acquiring an additional 9,844 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Alpine Immune Sciences by 23.4% in the first quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 1,697 shares in the last quarter. Barclays PLC boosted its holdings in Alpine Immune Sciences by 197.0% in the fourth quarter. Barclays PLC now owns 14,098 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 9,351 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in Alpine Immune Sciences by 33.1% in the fourth quarter. BlackRock Inc. now owns 728,848 shares of the biotechnology company’s stock worth $10,095,000 after acquiring an additional 181,066 shares in the last quarter. 77.00% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Alpine Immune Sciences in a research report on Friday. Zacks Investment Research lowered Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 22nd. Finally, Oppenheimer dropped their price target on Alpine Immune Sciences from $19.00 to $17.00 in a research report on Monday, March 7th.

About Alpine Immune Sciences (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Read More

Earnings History for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.